Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of South Carolina

About this trial

This study is to develop and test a medical health application based on cognitive behavioral therapy for insomnia and augmented with other evidence-based sleep interventions that address common sleep-related problems in opioid use disorder. An initial program will be built utilizing input from persons beginning medications for opioid use disorders.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

No experience of withdrawal symptoms in past 2 weeks

Being stabilized on buprenorphine

Initiated buprenorphine in past 3 months

Modified buprenorphine dose in past 3 months (e.g., reducing dose with goal of transitioning to vivitrol)

Disqualifiers

Current psychotic symptoms

Current active suicidal ideation

Severe visual impairment

Current use of benzodiazepines

Trial design

Design model

Parallel

Treatments tested in this trial

  • mHealth application and sleep health education

    Device

    Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity

  • Simplified mHealth application and sleep health education

    Device

    Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: mHealth applicationExperimental treatment 1 intervention
Group B: Control GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Enrollment feasibility/acceptability benchmark of at least 30 persons completing entire study period - Enrollment and retention percentages

To achieve a minimum enrollment and retention percentage of 75% throughout the 6-week investigation period.

Time frame
6 weeks following enrollment
2

Protocol adherence feasibility/acceptability benchmarks of participants completing modules and sleep diaries each week - Engagement

Completing at least one module per week, submitting a minimum of four sleep diaries per week, and implementing stimulus control and sleep restriction on at least 90% of nights.

Time frame
6 weeks following enrollment
3

mHealth App Usability Questionnaire

Validated measure of mobile app usability with 3 sections: Ease of use/satisfaction, system information arrangement, and usefulness

Time frame
6 weeks following enrollment

Secondary outcomes

1

Pittsburgh Sleep Quality Index

Validated measure of difficulty falling and staying asleep and subsequent daytime function

Time frame
At enrollment and 6 weeks following enrollment
2

Structured Clinical Interview for Sleep Disorders - Revised Edition

Assessment for sleep disorders based on the DSM-5

Time frame
At enrollment and 6 weeks following enrollment
3

Insomnia Severity Index

Global sleep quality; the most common self-reported sleep measure

Time frame
At enrollment and 6 weeks following enrollment
4

Daily Sleep Diary - Sleep Onset Latency

Subjective sleep onset latency (time to fall asleep)

Time frame
Through study completion of 6 weeks

Other outcomes

1

MOUD and drug use

Self-reported checklist

Time frame
Through study completion of 6 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Medical University of South Carolina

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator